Current use of enhanced external counterpulsation and patient selection

被引：9

作者：

Lawson, WE ^{[1
]}

机构：

[1] SUNY Stony Brook, Ctr Hlth Sci, Div Cardiol, Stony Brook, NY 11794 USA

来源：

CLINICAL CARDIOLOGY | 2002年 / 25卷 / 12期

关键词：

angina pectoris; congestive heart failure; coronary artery bypass graft; coronary artery disease; enhanced external counterpulsation (EECP); International EECP Patient Registry; Medicare;

D O I：

10.1002/clc.4960251406

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Most patients who receive enhanced external counterpulsation (EECP) have symptomatic coronary artery disease. These patients have either responded poorly to pharmacologic therapy or are poor candidates for revascularization procedures. Such patients receive a variety of consistent benefits from EECP treatment. As more is learned about EECP, patients once excluded from early clinical trials are now able to take advantage of EECP. Nevertheless, EECP is not suitable for some patients. It has a favorable adverse event profile for most patients undergoing the treatment. Medicare reimbursement coverage limitations remain an obstacle to having a broad cross-section of patients benefit from EECP.

引用

页码：16 / 21

页数：6